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 MuScle & TenDon
Role of microRNA in muscle regeneration 
and diseases related to muscle 
dysfunction in atrophy, cachexia, 
osteoporosis, and osteoarthritis
MicroRNAs (miRNAs) are a class of small non- coding RNAs that have emerged as potential 
predictive, prognostic, and therapeutic biomarkers, relevant to many pathophysiological 
conditions including limb immobilization, osteoarthritis, sarcopenia, and cachexia. Im-
paired musculoskeletal homeostasis leads to distinct muscle atrophies. Understanding 
miRNA involvement in the molecular mechanisms underpinning conditions such as mus-
cle wasting may be critical to developing new strategies to improve patient management. 
MicroRNAs are powerful post- transcriptional regulators of gene expression in muscle and, 
importantly, are also detectable in the circulation. MicroRNAs are established modulators 
of muscle satellite stem cell activation, proliferation, and differentiation, however, there 
have been limited human studies that investigate miRNAs in muscle wasting. This nar-
rative review summarizes the current knowledge as to the role of miRNAs in the skeletal 
muscle differentiation and atrophy, synthesizing the findings of published data.
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Article focus
 Accumulating evidence suggests a 
significant role of microRNA (miRNA) in 
muscle differentiation and an important 
role of miRNAs as regulators of muscle 
atrophy.
 This review summarizes the role of 
miRNAs in skeletal muscle differentiation 
and atrophy and offers future research 
directions.
 MicroRNAs are involved in muscle atro-
phies associated with different patho-
physiological conditions.
Key messages
 MicroRNAs regulate myogenesis, through 
the control of satellite cell quiescence, 
proliferation, and terminal differentiation.
 There is no consensus on how miRNA 
dysregulation alters the pattern of 
muscle wasting related to different 
pathophysiologies.
 More research is required to understand the 
involvement of miRNAs in muscle atrophy 
pathways before these targets can be used 
as clinical biomarkers.
Strengths and limitations
 Potential specific miRNAs are suggested as 
possible markers and therapeutic targets 
for muscle- related diseases, which can be 
considered for future studies.
 Although the actual details of how specific 
miRNAs affect muscle- wasting mecha-
nisms related to different pathophysiolo-
gies are limited, the current knowledge 
concerning which miRNAs are involved 
in each of the major disease area is 
summarized.
 In the future, as the literature in this field 
expands, more targeted, systematic 
reviews would be useful to explore detailed 
facets of the muscle miRNA literature, such 
as specific markers of the onset of muscle 
wasting following immobilization.
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Table I. MicroRNAs expressed in muscular tissue and their global effect on muscle biological process and their validated targets.
miR Biological process Tissue expression Validated mRnA targets Reference
miR-1 enhancer of skeletal muscle differentiation muscle- specific HDAC4,
Pax7, Pax3,
15–17,20,21
miR- 133a/b enhancer of myoblast proliferation muscle- specific FGFR1, PP2AC, PRDM16, SRF, 
IGF1
15
miR-206 enhancer of myoblast proliferation muscle- specific Notch3, IGFß, Meox2, RARB, 
Fzd7, MAPK3, CLCN3, NFAT5, 
Mstn, Smad3, Pax7
16,17,20,21
miR-27 a/b promotes entry into differentiation programme ubiquitous Mstn, Pax3 16,17,22
miR- 26a promotes myoblast differentiation ubiquitous Smad1, Smad4, Ccnd1, Ezh2 23
miR-221/222 promote cell cycle progression ubiquitous p27 22
miR- 146b promotes satellite cell differentiation ubiquitous Smad4, Notch1, Hmga2 24
miR- 26a promotes myoblast differentiation ubiquitous TGFß/BMP, Smad4 23
miR-155 represses myoblast differentiation ubiquitous TNF-α, Cdc25A 25
miR-503, miR-322/424 promote myogenesis interfering with the progression 
through the cell cycle
ubiquitous TNF-α, Cdc25A 25
miR- 29b enhancer of skeletal muscle atrophy ubiquitous Murf-1, Atrogin-1 12
BMP, bone morphogenetic protein 2; Cdc, cell division cycle; CLCL3, chloride voltage- gated channel 3; HDAC4, histone deacetylase 4; Hmga2, 
high mobility group at- hook 2; IGF, insulin- like growth factor; MAPK, mitogen- activated protein k ; miRNA, microRNA; mRNA, messenger RNA; 
Mstn, myostatin; Notch1, notch receptor 1; RARB, retinoic acid receptor beta; SRF, serum response factor; TGFß, tumour growth factor- beta; 
TNF-α, tumour necrosis factor- alpha.
Introduction
Skeletal muscle is critical for health throughout life. Loss 
of muscle mass is typically seen with ageing and occurs 
in many chronic diseases including cancer cachexia, 
osteoarthritis (OA), and type II diabetes mellitus. It can 
also present itself more acutely through disuse atrophy, 
evident as a result of bed rest and limb immobilization. 
All muscle atrophy conditions share common functional 
consequences, through the loss of muscle strength and 
power, reducing the ability to perform activities of daily 
living, with a resultant impact on a person’s quality of 
life. These are major causes of morbidity and are poor 
prognostic factors for many patients.1 The pathogen-
esis of muscle wasting appears to be multifactorial, 
involving inflammation, impaired muscle regeneration, 
oxidative stress, senescence, and apoptosis.2,3 Studies 
suggest that these complex cellular processes play a 
role in myofibre degeneration followed by satellite cell 
activation and differentiation.2,3 The muscle regenera-
tive response consists of activation of quiescent satel-
lite cells, proliferation of the myogenic precursor cells 
(myoblasts), and terminal differentiation into myocytes 
and their fusion into myofibres. However, failed 
myofibre regeneration and/or accelerated pathological 
processes that affect cellular homeostasis eventually 
lead to muscle atrophy.2,3 Therefore, an understanding 
of the formation of muscle (myogenesis), but also an 
understanding of molecular mechanisms underpinning 
muscle wasting, is critical to the development of prog-
nostic or therapeutic biomarkers.
MicroRNAs (miRNAs) belong to a class of small non- 
coding RNA species that post- transcriptionally alter 
gene expression by increasing translational repres-
sion or by inducing messenger RNA (mRNA) cleavage 
and degradation.4,5 They are involved in a variety of 
biological processes through their regulatory function 
in mechanisms of post- transcriptional gene expression 
(Table I).6-10 Cell and animal studies have demonstrated 
that miRNAs are altered during muscle cell prolifera-
tion, differentiation, apoptosis, and regeneration.2,3,6 
In recent years, miRNAs have emerged as regulators 
of skeletal muscle function and aberrant expression of 
miRNAs is thought to be associated with the progression 
of muscle atrophy in various diseases.11 For example, 
miR- 29b has been reported to be commonly upreg-
ulated in multiple types of muscle atrophy.12 miRNAs 
have been shown to play an important role in human 
embryonic myogenesis13 and also in adult myogenesis 
after injury.14 Individual miRNAs have been shown to be 
involved in myogenesis, through the control of satellite 
cell quiescence (miR-195, miR-497), proliferation (miR-
133, miR-27), and additionally myoblast differentiation 
(miR-206, miR-1, miR-486).15-19 In addition, miRNAs are 
secreted into extracellular fluids. Circulating miRNAs are 
attractive potential biomarkers for a variety of muscle 
atrophy conditions, which can also serve as signalling 
molecules to mediate intracellular communications. 
As such, these may be attractive prognostic and thera-
peutic biomarkers, which could serve as adjunct tools 
in the management of patients with muscle atrophies. 
This review describes the biogenesis and function of 
miRNAs, and highlights their role in skeletal muscle 
differentiation and regulation of muscle atrophy. The 
format of our review offers a perspective on the role 
of miRNAs in diseases related to muscle dysfunction 
investigated in different models. Due to a relatively 
low number of available publications, our study has 
used a narrative review format, which has allowed us 
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Fig. 1
MicroRNA (miRNA) biogenesis pathway. miRNAs are transcribed in the nucleus, generating primary miRNAs (pri- miRNAs) that undergo nuclear cleavage to 
form precursor miRNAs (pre- miRNAs). In the cytoplasm, pre- miRNAs are further processed by the Dicer. The double- stranded RNA duplex unwinds and then 
the mature single- stranded miRNAs assemble into RNA- induced silencing complex (RISC). The miRNA targets messenger RNA (mRNA) to either inhibit mRNA 
translation or induce mRNA cleavage and degradation.
to provide a “best- evidence synthesis” and relevant 
interpretation of the data. More specifically, the limita-
tions, which determined a narrative review format of 
this paper, result from: 1) small number of publications 
for specific miRNAs for particular muscle conditions 
in cohort studies; 2) discrepancies between in vitro, 
animal, and in vivo data; and 3) additional difficulty 
related to categorization of investigated models and 
confounding factors between them. As such, although 
this review is not exhaustive, it can serve as a guide for 
future work in this area.
The sources used for articles in this narrative review 
were PubMed and MEDLINE. They were searched using 
the keywords: ‘miRNA in skeletal muscle’, ‘miRNA 
role in atrophy and regeneration’, ‘miRNA in cancer 
cachexia’, ‘miRNA in sarcopenia’, ‘miRNA in bed immo-
bilization’, ‘miRNA in OA’, and ‘miRNA in osteoporosis’. 
The abstracts were reviewed and all that were relevant 
to the topic of our study were selected. Additionally, 
the quality of the publications was assessed based on 
the rank of the journal, and was further aided in some 
cases by taking into account the number of citations.
MicroRnA biogenesis and function. MicroRNAs are 
transcribed in the nucleus by the RNA polymerase II 
enzyme to produce a primary- miRNA transcript (pri- 
miRNAs), which can be several hundred base pairs in 
length.26 Pri- miRNAs form specific hairpin secondary 
structures and enter a microprocessor complex, which 
contains ribonuclease III enzyme Drosha, which cleaves 
pri- miRNAs at the 3' and 5' end, leaving an approxi-
mately 70- nucleotide stem- loop precursor miRNA (pre- 
miRNA). Pre- miRNAs are exported from the nucleus 
to the cytoplasm via EXPORTIN 5, a nuclear transport 
protein, which recognizes double- stranded RNAs. In 
the cytoplasm, pre- miRNAs are further processed by 
the endoribonuclease Dicer to a short double- strand 
miRNA duplex, leaving a short double- stranded RNA 
duplex, which harbours the mature miRNA. The 
double- stranded RNA duplex unwinds and then the 
mature single- stranded miRNA associates with the RNA- 
induced silencing complex (RISC). This RISC consists of 
multiple proteins27 and when it binds with the miRNA it 
forms the miRNA- induced silencing complex (miRISC). 
As part of the miRISC, miRNAs can then interact with 
the untranslated region 3′ (3′UTR) of target messenger 
RNAs (mRNAs) and either inhibit their translation or in-
duce mRNA cleavage and degradation (Figure 1).
Muscle stem cells. Skeletal muscle has a high regener-
ative capacity in response to injury and exercise. This 
regenerative potential is fulfilled by myogenic precur-
sors known as satellite stem cells (SSCs), which express 
characteristic paired- box transcription factors, such as 
Pax7 and Pax3.28–30 SSCs reside beneath the basal lam-
ina, closely juxtaposed to the plasma membrane, and 
are mitotically quiescent in adults.31 They are activated 
in response to stimulation (such as muscle injury or ex-
ercise) by re- entering the cell cycle. This results in satel-
lite cell proliferation and myofibre regeneration. It has 
been demonstrated that during this time SSCs encoun-
ter different fates (Figure  2). The majority are a fast- 
dividing population of Pax7+MyoD+ cells that undergo 
limited replication before myogenesis and are commit-
ted to differentiation, whereas a minor population of 
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Fig. 2
Satellite stem cell differentiation process. In healthy adult muscle, satellite cells remain in a nonproliferative, quiescent state. They are activated in response to 
muscle injury or exercise. Activated satellite cells proliferate, undergo self- renewal, and differentiate into myoblasts and then to myocytes, which can mutually 
fuse and generate myotubes. During this time, the satellite stem cells encounter different fates. Quiescent satellite cells are characterized by the expression 
of transcription factors Pax7 and Pax3, whereas activated satellite cells coexpress Pax7 and myogenic differentiation factors Myf5 and MyoD. Activation of 
MyoG and Mrf4 characterizes the terminally differentiated myocyte. Diseases can impair satellite cell activation and proliferation, resulting in the inhibition of 
terminal differentiation.
slow- dividing Pax7+MyoD– cells revert to quiescent self- 
renewing cells.32,33
Role of miRnA in controlling skeletal muscle 
differentiation
Myogenesis is an ordered multi- step process during 
which activated SSCs stop proliferating, undergo differ-
entiation, and fuse into myotubes (Figure  2).20 This 
involves a complex of transcriptional mediators but also 
non- coding RNA molecules. Satellite cells maintain the 
myogenic regulatory factors (MRFs), which are required 
for myogenic determination. Primary MRFs, such as 
myogenic differentiation (MyoD) and myogenic factor 
5 (Myf5), act as determination genes, which initiate an 
early stage of myogenesis and characterize proliferating 
progenitor cells, known as myoblasts. Secondary MRFs, 
myogenin (MyoG) and myogenic factor 6 (Mrf4), are 
specific to late- stage myogenesis and characterize the 
terminally differentiated myocyte. In addition, the MRF 
family interacts synergistically with myocyte enhancer 
factor 2 (Mef2) to activate skeletal muscle- specific tran-
scription promoters. Expression and splicing changes 
of Mef2 proteins isoforms Mef2A, Mef2C, and Mef2D in 
response to MyoD are consistent with the observation 
that the majority of skeletal muscle genes require both 
MyoD and Mef2 family members to activate myogen-
esis. Therefore, Mef2 appears to play a specific role in 
early events of cell differentiation. The whole process 
is followed by fusion into regenerating fibres. Disrup-
tion of this network entirely abrogates skeletal muscle 
formation, regenerative potential, and remodelling.
Recent studies have incorporated miRNAs into the 
complex myogenicregulatory network. Within skel-
etal muscle, the 'muscle- specific' miRNAs (e.g. miR-1, 
miR- 133a, and miR-206) play a central role in muscle 
biology and are all induced during differentiation of 
myoblasts into myotubes. However, regulation between 
myogenic transcription factors and miRNAs is complex 
and depends on the cell cycle and fusion stages. 
For instance, overexpression of miR-1 or miR-206 in 
myoblasts leads to accelerated differentiation into 
myotubes accompanied by a decrease in cell prolifera-
tion.17-19 The overexpression of miR-1 leads to decreased 
levels of histone deacetylase 4 (HDAC4) protein in 
C2C12 cells,17 and the overexpression of HDAC4 has 
been demonstrated to repress both myoblast differenti-
ation and Mef2 dependent transcription.21 Conversely, 
overexpression of miR-133 promotes myoblast prolifer-
ation and decreases serum response factor (SRF) levels, 
thus preventing SRF- mediated inhibition of myoblast 
proliferation.17 MicroRNAs also play a modulatory role 
in the upstream regulation of muscle stem cell factors 
such as Pax3 and Pax7; miR-1, miR-27, and miR-206 all 
inhibit Pax3,18,19 whereas miR–1 and miR-206 repress 
Pax722,34 and thus promote the terminal differentiation 
of myoblasts downstream of MyoD. However, the inhi-
bition of miR- 27b maintains Pax3 expression and delays 
differentiation. While some miRNAs are upregulated 
during the first stage of differentiation, others, such 
as miR-221 and miR-222, are downregulated,24 which 
is correlated with elevated expression of the cell cycle 
inhibitor p27 (the target of both miR-221 and miR-222). 
Overexpression of miR-221 and miR-222 delays cell 
cycle withdrawal and differentiation.24
More recently, an abundance of miRNA-489 has 
been identified in quiescent satellite cells and it has 
been shown that this is quickly downregulated during 
satellite cell activation, while satellite cells that lack a 
functional miRNA pathway spontaneously exit the 
quiescent stage and enter the cell cycle.23 Furthermore, 
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miR-195 and miR-497 have been shown to play a role in 
the maintenance of quiescence in juvenile muscle stem 
cells, by targeting the cell cycle genes, cell division 
cycle 25 (Cdc25), and cyclin d2 (Ccnd).15 These findings 
are particularly relevant to the development of muscle 
stem cell therapies, as manipulation of these miRNAs 
prior to transplantation may prompt more efficient 
regeneration of muscle. A novel miR- 146b has also been 
found among the miRNAs that are upregulated during 
satellite cell activation and myoblast differentiation. It 
was proposed that its upregulation is accompanied by 
downregulation of the target genes such as Smad family 
member 4 (Smad4), notch receptor 1 (Notch1), and high 
mobility group at- hook 2 (Hmga2) in order to allow the 
activation of myogenic differentiation programme.25 It 
is believed that miR- 26a and miR- 146b act together to 
regulate Smad4 during myogenesis. In vitro cell culture 
and animal studies established that miR- 26a promotes 
muscle differentiation and regeneration by downregu-
lating, signalling pathways that inhibit differentiation, 
(TGF-ß/BMP) as well as smad family member 1 and 4 
(Smad1, Smad4), by targeting specifically 39 3′ UTRs.35 
A recent study has not only established the role of miR- 
26a for skeletal muscle development in vivo but also its 
regulatory role in muscle differentiation and regenera-
tion through myogenesis repression.35
Furthermore, recent in vitro and in vivo (rodent) 
studies have shown that miR- 27a/b plays a role in: 1) 
the activation of satellite cells and their self- renewal; 
2) myoblast proliferation; and 3) accelerated muscle 
regeneration through negative regulation of myostatin 
(Mstn).16,17 The loss of Mstn activates satellite cells, 
increasing muscle growth and regeneration, whereas 
its increased level leads to muscle atrophy through 
protein degradation and blocked protein synthesis.16 
Associated with the loss of Mstn, there is myoblast acti-
vation with an increased number of Pax7 and MyoD 
positive cells, followed by miR- 27a activation due to 
loss of Mstn. On the other hand, it has also been shown 
that miR-27 downregulates PAX3 protein levels without 
affecting the level of PAX7.18 However, Mstn has also 
been shown to be a negative regulator of Pax7 expres-
sion, therefore the increased number of Pax7 positive 
cells are more likely due to miR-27- mediated inhibi-
tion of Mstn rather than to direct regulation of Pax7 
by miR-27. Furthermore, in vivo skeletal muscle treat-
ment with miR- 27a/b- specific antago- miRs has been 
shown to result in significant reduction in the numbers 
of Pax7+cells and activated myoblasts (MyoD+), which 
further confirms that miR-27 is capable of Mstn regula-
tion.16 Satellite stem cell impairment is consistent with 
Smad3 loss associated with increased levels of Mstn 
and decreased levels of miR-27, reported in Smad3- 
null mice. It has been shown that treatment with Mstn 
increased miR- 27a/b expression, which was dependent 
on the activity of Smad3. Taken together, this evidence 
indicates that there is an autoregulatory mechanism in 
which Mstn, via Smad3 signalling, regulates miR- 27a/b 
expression, which is responsible for satellite activation 
during muscle regeneration.16 To date several miRNAs 
have been identified that play a role in muscle stem 
cell activation and myogenesis, which offer the future 
prospect of being able to activate myogenesis directly. 
However, it will be important for further work to 
provide evidence that manipulation of these miRNAs 
can reduce or reverse muscle injury and muscle wasting 
in pre- clinical models.
Role of miRnA in skeletal muscle in 'in vitro' 
models
Inflammatory cytokine-induced muscle atrophy. The 
atrophic loss of muscle mass can be triggered by tu-
mour necrosis factor (TNF-α) and insulin- like growth 
factor (IGF) that regulate myogenesis through com-
plex signalling pathways that affect muscle gene ex-
pression. The physiological role of TNF-α links nucle-
ar factor kappa B (NF-κB) with its inhibitory effect on 
muscle differentiation through the negative regulation 
of myogenic regulatory factors (MRFs). Conversely, IGF 
activates NF-κB, which increases both myoblast prolifer-
ation and differentiation. A recent in vitro study showed 
that the TNF-α inhibitory effect on muscle myogene-
sis is mediated by regulatory miRNAs.36 A small num-
ber of miRNAs are regulated by TNF-α or IGF1. TNF-α 
stimulates expression of miR-155, which is repressed 
during myoblast differentiation, but overexpression of 
miR-155 inhibits myotube formation. TNF-α induces 
miR-503 downregulation during myoblast differentia-
tion whereas miR-503 expression is upregulated dur-
ing myotube formation. Parallel inhibition of miR-155 
and overexpression of miR-503 protects against the 
inhibitory effect of TNF-α on myotube formation. It is 
postulated that intervention at the miRNA level may 
reduce the inhibitory effect of proinflammatory TNF-α 
and thereby indirectly induce myoblast differentiation. 
TNF-α induced suppression of myoblast differentiation 
was demonstrated to be relieved by overexpression of 
miR-1, miR-206, and miR- 133a/b in the murine C2C12 
cell- line.37 This beneficial effect can be considered as an 
innovative therapeutic strategy in the context of skele-
tal muscle atrophy. It has been suggested that biogen-
esis of some miRNAs is modulated by both TNF-α and 
IGF1 via mitogen- activated protein k (MAPK) signalling 
pathway and that this might have therapeutic signifi-
cance.36 TNF- like weak inducer of apoptosis (TWEAK) is 
an inflammatory cytokine, which belongs to the TNF 
super ligand family, but is more potent than its struc-
tural counterpart TNF-α. TWEAK treatment of C2C12 
myotubes resulted in the inhibition of miR-1 to 1, miR-1 
to 2, miR- 133a, miR- 133b, and miR-206, while miR- 146a 
and miR-455 were increased.38 Collectively the gene 
targets of miRNAs modulated by TWEAK are involved in 
the inflammatory response, fibrosis, extracellular matrix 
remodelling, and proteolytic degradation.38
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Fig. 3
The involvement of microRNAs (miRNAs) in muscle atrophy associated with 
cancer cachexia, sarcopenia, prolonged inactivity, and dexamethasone- 
induced atrophy. MicroRNA-23 and miR-206 downregulation affects the 
expression of transcription factor Pax7 in satellite stem cells, promoting 
muscle mass wasting during prolonged activity.42 Following dexamethasone 
treatment, miR-182 suppresses forkhead box O3 (FOXO3) at the messenger 
RNA (mRNA) and protein level, which induces atrophy.40 In sarcopenia, miR-
29, miR- 125b, miR-143- 3p, and let-7 have been shown to impair myogenesis 
by targeting insulin- like growth factor 1 (IGF-1) and cyclin- dependent kinase 
6 (CDK6).43 In mice muscle, miR-431 was overexpressed and the muscle has 
shown reduced Smad4 level, which increases during ageing.44 Interactions 
between miRNA and mRNA have been identified in cancer cachexia muscle 
wasting. They include miR- 199a/caveolin 1 (Cav1), miR- 199a/transcription 
factor Jun- B (Junb), miR- 27a/FOXO1, miR- 145a/FOXO1, miR- 27a/myocyte 
enhancer factor 2 (Mef2C), and miR- 27b/Mef2C.45 STAT3, signal transducer 
and activator of transcription 3.
Dexamethasone-induced muscle atrophy. Dexamethasone 
is a corticosteriod used for the treatment of a various 
inflammatory- related conditions, as well as being an ad-
junctive treatment in cancer patients undergoing chemo-
therapy. Dexamethasone is widely used in in vitro muscle 
systems to induce muscle atrophy. A number of studies 
have reported that miRNAs play a role in dexamethasone- 
induced atrophy in cultured muscle cells.39-41 High- 
throughput analysis of miRNAs using microarrays indicates 
there are multiple candidate miRNAs which are altered by 
dexamethasone- induced atrophy.39 Dexamethasone treat-
ment of C2C12 myotubes led to the upregulation of 11 
miRNAs and downregulation of six miRNAs. Independent 
validation by stem- loop real- time quantitative reverse tran-
scription polymerase chain reaction (RT- PCR) confirmed 
six miRNAs were differentially expressed including miR-1, 
miR-147, miR-332, miR-351, miR-503, and miR-708. The 
targets of these miRNAs include many muscle growth 
and atrophy- related genes.39 Another study showed that 
transfection of miR-182 into C2C12 myotubes treated with 
dexamethasone significantly suppressed forkhead box O3 
(FoxO3) transcriptional factors at the mRNA and protein lev-
el (Figure 3). Furthermore, transfection of miR-182 which 
targets the 3′ UTR of FoxO3, also resulted in the down-
regulation of multiple targets which are transcriptionally 
regulated by FoxO3, including F- box protein coding genes 
(Mafbx and Atrogin-1) among others.40 Intriguingly, extra-
cellular miR-182 levels were increased in the cell culture 
media following dexamethasone treatment of C2C12 
myotubes,41 which suggests miR-182 may be actively or 
passively released during glucocorticoid- induced atrophy.
Role of miRnA in immobilization
localized immobilization-induced muscle atrophy. 
Regular mechanical loading is essential for the mainte-
nance of muscle mass and function. Limb immobiliza-
tion or hind limb suspension leads to localized skeletal 
muscle atrophy. This model represents changes within 
muscles, which may appear after the conservative treat-
ment of long bone fractures using plaster casts. High- 
throughput profiling of miRNAs in the soleus muscle af-
ter two to seven days hind limb suspension in an animal 
model revealed changes in 18 miRNAs. Reduced miR-
499 and miR- 208b were identified as potential regula-
tors of the muscle atrophy. Both of these markers were 
reduced even further after longer periods (observed 
up to 28 days) of hind limb suspension. Conversely, 
expression of miR-499, which targets SRY- box tran-
scription factor 6 (Sox6), was increased. Sox6 target is 
established as negative regulators of ß-myosin heavy 
chain (ß-MHC), which encodes the contractile protein 
of the myosin heavy chain.46 Another study identified 
that the miR-30 family was downregulated by hind 
limb suspension. Similar changes in the miR-30 family 
were observed in dystrophic Mdx4cv compared to wild- 
type mice. SWI/SNF- related matrix- associated actin- 
dependent regulator of chromatin subfamily D mem-
ber 2 (Smarcd2), snail family transcriptional repressor 2 
(Snai2), and trinucleotide repeat containing adaptor 6a 
(Tnrc6a) were validated as miR-30 family targets, which 
may indirectly modulate other myogenic miRNAs such 
as miR-206.47 Muscle unloading also occurs under zero 
gravity conditions: one previous study revealed that 11 
days of spaceflight resulted in transcriptional modu-
lation of several hundred genes, notably miR-206 ex-
pression in gastrocnemius was found to be significantly 
decreased.48
Bed rest-induced muscle atrophy. Bed rest and lack of 
all physical activity in comparison with limb immobili-
zation can induce well- recognized systemic metabolic 
changes such as decreased cardiovascular function, de-
creased muscle function, and increased insulin resist-
ance.49 This model can be used to mimic physiological 
changes and the consequences of sustained inactivity 
and unloading, which occurs in some patients after trau-
ma. Analysis of the vastus lateralis muscle in six males 
after ten days of bed rest showed downregulation of 
miR-206, a factor responsible for muscle function main-
tenance, and also a downregulation of miR- 23a, a factor 
responsible for insulin messaging and defence against 
muscle atrophy (Figure 3).42 However, it has been shown 
that resistance training induces miR-206 upregulation 
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and thus activates SSC proliferation, enhancing mus-
cle differentiation.50 Downregulation of miR-23 shows 
an overlap with the dexamethasone- treated patients 
where the expression of this miRNA was also decreased, 
highlighting the role of this miRNA in muscle homeo-
stasis.48 Rezen et al42 has shown that several members of 
the let-7 family, which affects the cell cycle and insulin 
resistance, were also downregulated. However, another 
study on vastus lateralis muscle samples, after a 21- day 
bed rest period, showed that the let-7 family of miRNAs 
was upregulated. This miRNA group is increased in type 
II diabetes mellitus and is associated with inactivity.51 
Furthermore, the let-7 group is upregulated in mus-
cle samples from the elderly, suggesting an overlap of 
the mechanisms involved in the response to unloading 
and ageing.52 Patients in intensive care units (ICUs) are 
characterized by long- term immobilization, bed rest, 
and artificial ventilation, leading to accelerated muscle 
wasting. Respiratory muscle is particularly susceptible 
to wasting, when artificial ventilation is necessary. One 
clinical study has assessed miRNA expression in mus-
cle of septic ICU patients, which reported an increase 
in primary miR-21 levels, but not in its mature form 
of miR-21, which suggests that impairment of miR-21 
processing may occur in muscles of ICU patients.53 This 
group of patients represents both bed rest- induced as 
well as cytokine- induced muscle atrophy.
Role of miRnA in skeletal muscle atrophy
cancer cachexia. Cancer cachexia is a complex syn-
drome that affects patients with advanced cancer and 
impacts adversely on quality of life, morbidity, and 
mortality.54 In cancer patients, there is a wide variation 
in muscle atrophy and some patients appear to be more 
susceptible to cachexia. New interactions between 
miRNA and mRNA have been identified in cancer ca-
chexia muscle wasting. These include miR- 27a/FOXO1, 
miR- 27a/Mef2C, miR- 27b/Cxcl12, miR- 27b/Mef2C, 
miR-140/Cxcl12, miR- 199a/caveolin 1 (Cav1), and miR- 
199a/Junb.45 MicroRNA- 27a and miR- 27b have been 
shown to regulate Mef2, the gene responsible for acti-
vation of skeletal muscle- specific transcription promot-
ers during muscle regeneration.45,55 MicroRNA- 27b has 
also been shown to downregulate myostatin (Mstn), 
a member of the transforming growth factor β (TGFβ) 
family, responsible for SSC activation and myoblast 
proliferation. Jiang et al56 have demonstrated that an in-
crease in miR- 145a decreased forkhead box O1 (FOXO1) 
expression, suggesting that miR- 145a should be con-
sidered as a potential regulator during muscle decline 
in cancer cachexia. In addition, miR-199 has been 
linked to Cav1 and transcription factor Jun- B (Junb) 
regulation. Junb regulates gene expression on multiple 
levels, however it has been shown to interact with sig-
nal transducer and activator of transcription 3 (STAT3), 
which contributes to cancer cachexia (Figure  3).57 
High- throughput sequencing of small RNAs in skeletal 
muscle from cachexia patients may further help to re-
veal novel therapeutic targets within muscle. However, 
muscle itself may also be a source of extracellular miR-
NAs. Microvesicles provide intracellular transport for 
different proteins and miRNAs, which are present in 
many different tissues. A study on miRNAs transported 
in microvesicles revealed the presence of miR-21, which 
was secreted by tumour cells, and which induced con-
comitant myoblast cell death.58 Microvesicles harbour-
ing miR-21 were proposed to fuse with muscle cells and 
to activate toll like receptor (TLR7/8), leading to apopto-
sis.58 In this respect, repeated measurements of circulat-
ing miRNAs over several timepoints in cancer patients 
would be valuable for the discovery of novel miRNA bi-
omarkers which can track muscle wasting.
Sarcopenia. In adult humans, muscle mass is lost at a 
rate of ~1%/year after the age of 30 years.59 This pro-
cess is thought to decrease regenerative capacity in the 
muscle.2 Sarcopenia is defined as an age- related muscle 
decline. It develops by itself and often progresses inde-
pendently of coexisting comorbidities that are associ-
ated with the chronic inflammatory state.60 The role of 
miRNA in ageing muscle is complex and confounded 
by factors such as physical activity. A total of 26 miRNAs 
have been identified to be regulated by age and exer-
cise, but the interaction of these factors has also been 
shown to affect miRNA expression.61 Investigation of 
the role of miRNAs in sarcopenic patients has shown up 
regulation of both has- miR- 34a- 5p and has- miR- 449b- 
5p. These miRNAs significantly increased the expression 
of a key senescence gene sirtuin 1 (SIRT1) and other 
genes related to the mitogen- activated protein kinase 
(MAPK) pathway, which regulate ageing processes.62 
Additionally, IGF-1 and cell cycle regulators such as 
cyclin- dependent kinase 6 (CDK6) are downregulated 
in ageing muscles. MicroRNA-29, miR- 125b, miR-143 to 
3 p, and let-7 have been shown to impair myogenesis 
by targeting IGF-1 and CDK6 (Figure 3).43
Similarly, transforming growth factor β (TGF-β) gene 
has been shown to play an important part in sarco-
penia and to be excessively activated in skeletal muscle 
ageing.44 It has been demonstrated that miR- 26a, 
miR-675, miR- 146b, and miR-431 inhibit TGF-β signal-
ling and improve muscle regeneration. Interestingly, 
when miR-431 was overexpressed in mice, it improved 
myogenic capacity of myoblasts. Likewise, when it 
was injected into mice muscle, the muscle has shown 
reduced Smad family member 4 (Smad4) levels, which 
increase during ageing (Figure  3). In conclusion, this 
study highlighted a possible role of miR-431 as a thera-
peutic target in muscle ageing.44
Role of miRnA in related disorders
osteoporosis. Osteoporosis is the most common met-
abolic bone disease, characterized by decreasing bone 
quantity over time, leading to decreased bone strength. 
Like sarcopenia, osteoporosis is an age- related disease 
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and there is a growing consensus that the two diseases 
share common pathways including reduced anabolic 
hormone sensitivity, increased cytokine activity, and 
possibly even miRNA expression patterns.63 The role of 
miRNA in bone homeostasis and their effect on oste-
oblast or osteoclast differentiation, function, and ap-
optosis has been established. Some miRNAs (including 
miR-21 and miR-148) have been suggested as biomark-
ers for early diagnosis of osteoporosis. However, no 
specific diagnostic or predictive miRNA has proven to 
be efficient in clinical practice.64 As discussed, miR-21 
has been shown to be upregulated in muscles of immo-
bilized ICU patients and it has been shown to be a miR-
NA of interest in cancer cachexia.58 These results sug-
gest that miR-21 plays an important role in homeostasis 
of the musculoskeletal system, however more research 
is required to understand its specific function in distinct 
muscle atrophies.
osteoarthritis. Osteoarthritis (OA) is a multifactorial 
disease characterized by joint degeneration and patho-
logical changes in musculoskeletal tissues such as the 
synovium, cartilage, and ligaments. Chondrocytes 
in OA are dysregulated, producing matrix- degrading 
enzymes. In short, inflammatory and biomechanical 
stress signalling pathways are similar and they induce 
and overexpress cytokines and chemokine genes. It re-
mains controversial whether inflammatory mediators 
are primary or secondary regulators of cartilage dam-
age in OA, however biomechanical stress, inflammato-
ry changes, and muscle changes may all be linked and 
influenced by miRNAs.65,66 Periarticular loss of muscle 
bulk and function is well reported in OA, however the 
pathway and cross- communication between the OA 
joints and their effect on muscle is not well under-
stood. MicroRNA-143 is differentially expressed in the 
cartilage of the elderly suffering with OA.67 Likewise, 
miR-143 was demonstrated to regulate senescence of 
satellite cells and adult muscle stem cells via insulin- 
like growth factor binding protein 5 (IGFBP5), suggest-
ing a link between OA and muscle.68 Similarly, miR-181 
was downregulated in sarcopenic muscle samples69 
and a further study has demonstrated that the inhibi-
tion of this miRNA attenuates OA in animal models.70 
Another miRNA, which suggests a link between muscle 
metabolism and OA, is the downregulation of miR-378 
in elderly patients. This specific miRNA is responsible 
for muscle metabolism, myogenesis, and autophagy.68 
Synovial samples taken from late- stage OA joints have 
identified changes in miR-378 expression. Interestingly, 
miR-378 has been proven to be a pro- bone regenera-
tion molecule.71 These results cumulatively suggest 
that miR-378 can be considered as a factor involved 
in musculoskeletal homeostasis and a link between 
OA and the associated muscle changes. Importantly, 
miRNA analysis has shown that the function of miRNA 
is context- dependent and therefore a question aris-
es whether miRNA- associated mechanisms of muscle 
wasting are similar or different in OA.72 To date many 
individual miRNAs have been identified to influence 
the local pathogenesis within the synovium and carti-
lage, affecting the expression of signalling molecules 
including tumour necrosis factor (TNF-α), interleukin 1 
(IL-1), and interleukin 6 (IL-6), however apart from the 
discussed associations, no clear miRNA has been iden-
tified as a systemic biomarker predicting muscular phe-
notype or functional status of patients.73
In conclusion, there is accumulating evidence, from 
both in vitro and preclinical in vivo studies, that miRNAs 
play a key role in muscle differentiation and are important 
regulators of muscle atrophy. This narrative review high-
lights that there is no consensus on how miRNA dysreg-
ulation alters the specific muscle wasting related to 
different pathophysiologies and may serve as a guide 
for future studies in this area. There are some promising 
candidate miRNAs, miR-21 and miR-431, identified in 
preclinical studies, which now need to be confirmed in 
human muscle disorder clinical trials. However, inter-
ventional clinical trials investigating putative miRNA 
drugs have exhibited significant efficacy in a range of 
other health conditions, including hepatitis, patholog-
ical fibrosis, cancer, and kidney disease.74 Specifically, the 
therapeutic effect of miR-29 was studied in keloid and 
scar tissue formation, and miR-155 was investigated for 
treatment of T cell lymphoma, clearly suggesting a viable 
future for miRNA therapeutic agents in various diseases.74 
Considering the notable role of miR-2912 and miR-15536 in 
the muscle, the two miRNA drugs highlight a therapeutic 
potential of these biomarkers for muscle- related atrophy 
and dysfunction.
Current research has not outlined a definitive role of 
specific miRNA in muscle health and disease. The majority 
of studies evaluating muscle decline are performed in 
animal (quadrupedal) models. Therefore, the discrep-
ancies of published data do not take into account the 
differences in studied species, skeletal muscle biopsy 
sites, age of studied animals, and the physiological 
as well as locomotor kinematic differences between 
quadrupedal animals and bipedal species (humans). 
Moreover, the time course of miRNA changes, with the 
development and progression of muscle atrophy, has not 
been determined in a longitudinal study. To date most 
work compares miRNAs identified in atrophy to healthy 
muscle, which reflect the consequences of, rather than 
the cause, of atrophy.
Future studies should also consider the complicated 
nature of miRNAs and that confounding factors can 
alter up- or downregulation of these targets. In order 
to understand better how miRNAs affect expression and 
function of muscle genes, further work is needed to inves-
tigate the mechanisms which control the biogenesis of 
miRNA. RNA- binding proteins have been identified as the 
upstream modulators of miRNA, however more research 
is required to identify these proteins, their role on miRNA, 
and the extracellular cross talk between different organs 
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that induce their action. The majority of miRNA research 
has identified specific miRNA targets, which are dysregu-
lated in human disease, however to implement preventa-
tive therapies we need to better understand the processes 
which lead to the miRNA dysregulation in the first place. 
A clearer understanding of this process may offer the 
opportunity to identify key targets in disease pathogen-
esis for predictive and therapeutic biomarkers. Finally, 
through translational medicine research more effort 
needs to be placed on developing novel, sensitive, and 
specific clinical tests that identify the deregulated miRNA 
biomarkers in a patient’s blood and tissue biopsies.
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